By Josh Beckerman
Shares of biopharmaceutical company Azitra were recently 5% lower at $4.75 in their Friday debut on NYSE American, after an initial public offering of 1.5 million shares priced at $5 each.
The company said Tuesday that it expected the IPO price would be between $4.50 and $5.50.
Azitra plans to use the proceeds for purposes including clinical trials and product development, research and development, and for clinical manufacturing.
Write to Josh Beckerman at [email protected]
Read the full article here
